araag2/HINT huggingface dataset:
Clinical trial NCT02137343 (phase 3, status: terminated)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: rilotumumab, placebo, cisplatin, capecitabine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    all amgen sponsored amg102 clinical studies were terminated following a pre-planned data
    monitoring committee safety review of study 20070622.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ
             adenocarcinoma.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

          -  Tumor MET-positive by immunohistochemistry (IHC).

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
             criteria.

          -  Male or female subject greater than or equal to 20 years of age at the time of
             informed consent.

        Key Exclusion Criteria:

          -  Human epidermal growth factor receptor 2 (HER2)-overexpressing locally advanced or
             metastatic gastric or GEJ adenocarcinoma.

          -  Previous systemic therapy for locally advanced or metastatic gastric or GEJ or lower
             esophageal adenocarcinoma.

          -  Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant
             chemotherapy or chemoradiotherapy to randomization.

          -  Squamous cell histology.
Clinical trial NCT02138136 (phase 3, status: completed)
Conditions: constipation - functional
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: lubiprostone
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Has completed the 3-month placebo-controlled study (NCT02042183)

          -  Will continue to abstain from taking concomitant medication (prescribed or
             over-the-counter) that affects gastrointestinal motility

        Exclusion Criteria:

          -  Has untreated faecal impaction at the time of rolling over into study

          -  Has significant change in medical status, newly diagnosed and uncontrolled
             cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other
             systemic disease

          -  Has demonstrated non-compliance with study protocol during the 3-month
             placebo-controlled study (NCT02042183)
Clinical trial NCT02141399 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: alks 5461
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
Eligibility criteria:

        Inclusion Criteria:

          -  Agree to use an approved method of contraception for the duration of the study

          -  Have the potential to safely benefit from the administration of ALKS 5461

          -  Have a diagnosis of major depressive disorder (MDD)

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Have a positive test for drugs of abuse

          -  Currently pregnant or breastfeeding

          -  Have a current primary Axis-I disorder other than MDD

          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid
             antagonists (eg, naloxone, naltrexone) within 14 days

          -  Have received electroconvulsive therapy treatment within the last 2 years, or received
             more than 1 course of electroconvulsive treatment during their lifetime

          -  Have attempted suicide within the past 2 years

          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid
             antagonists (eg, naltrexone, naloxone)

          -  Have had a significant blood loss or blood donation within the past 60 days

          -  Additional criteria may apply
Clinical trial NCT02143570 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: darifenacin
SMILES: NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with overactive bladder as diagnosed and confirmed by a urologist.

          -  Able to answer the ICIC, King's Health Questionnaire and Overactive Bladder
             Questionnaire.

          -  Able and willing to receive urodynamic studies.

        Exclusion Criteria:

          -  History of pelvic radiotherapy.

          -  Recent pelvic surgery (<1 year).

          -  History of anti-incontinence surgery.

          -  Pregnancy.
Clinical trial NCT02143713 (phase 3, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: elagolix
SMILES: COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has completed the 6-Month Treatment Period in pivotal study M12-671.

          -  Agrees to use required birth control methods during the study through Month 6 of the
             Post-treatment Follow-up period

        Exclusion Criteria:

          -  Clinically significant gynecological condition

          -  Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine,
             femoral neck or total hip

          -  Plans to become pregnant in the next 18 months
Clinical trial NCT02147158 (phase 3, status: completed)
Conditions: leiomyoma, uterine hemorrhage
ICD codes: D25.0, D25.1, D25.2, D25.9
Drugs: ulipristal acetate (upa), placebo
SMILES: CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal women, 18-50 years, inclusive.

          -  Cyclic abnormal uterine bleeding (heavy or prolonged).

          -  Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in
             the first 8 days of menses.

          -  Minimum of one discrete leiomyoma observable by transvaginal ultrasound.

          -  Endometrial biopsy without evidence of malignancy or atypical or non-atypical
             hyperplasia.

        Exclusion Criteria:

          -  History of uterine surgery that would interfere with the study endpoints.

          -  Known coagulation disorder including bleeding disorder or clotting disorder.

          -  History of, or current uterine, cervix, ovarian, or breast cancer.

          -  Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP),
             or total bilirubin two times or greater than the upper limit of normal range.
Clinical trial NCT02147197 (phase 3, status: completed)
Conditions: leiomyoma, uterine hemorrhage
ICD codes: D25.0, D25.1, D25.2, D25.9
Drugs: ulipristal acetate (upa), placebo
SMILES: CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-menopausal women, 18-50 years, inclusive.

          -  Cyclic abnormal uterine bleeding (heavy or prolonged).

          -  Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in
             the first 8 days of menses.

          -  Minimum of one discrete leiomyoma observable by transvaginal ultrasound.

          -  Endometrial biopsy without evidence of malignancy or atypical or non-atypical
             hyperplasia

        Exclusion Criteria:

          -  History of uterine surgery that would interfere with the study endpoints.

          -  Known coagulation disorder including bleeding disorder or clotting disorder.

          -  History of, or current uterine, cervix, ovarian, or breast cancer.

          -  Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP),
             or total bilirubin two times or greater than the upper limit of normal rang
Clinical trial NCT02149121 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituxan, mabthera
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Patient is male or female between 18 and 75 years old, inclusive.

          2. Patient has a diagnosis of RA according to the revised 1987 ACR classification
             criteria (Arnett et al 1988) for at least 6 months prior to randomization.

          3. Patient has active disease as defined by the presence of 6 or more swollen joints (of
             66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL
             (≥15 mg/L) or an ESR ≥28 mm/hour.

          4. Patient has experienced an inadequate response to previous or current treatment with
             the anti-TNF agents infliximab

          5. Patient has a proper discontinuation period after treatment with interleukin-1
             receptor (IL-1R) antagonist, interleukin-6 receptor (IL-6R) antibody, or abatacept.

        Exclusion Criteria:

          1. Patient has taken more than 2 biologic agents.

          2. Patient has previously been administered Rituximab or participated in a Rituximab
             biosimilar study.

          3. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized
             proteins.

          4. Patient has current or past history of chronic infection with hepatitis B, hepatitis
             C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive
             result to the screening test for these infections.

          5. Patient has an infection requiring oral antibiotics 2 weeks before randomization,
             parenteral injection of antibiotics 4 weeks before randomization, other serious
             infection 6 months before randomization, a history of recurrent herpes zoster or other
             chronic or recurrent infection 6 weeks before randomization.
Clinical trial NCT02149199 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol 'as needed' + budesonide placebo bid, terbutaline 'as needed' + placebo budesonide bid, budesonide bid + terbutaline 'as needed'
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        INCLUSION CRITERIA 1. Provision of informed consent prior to any study specific procedures.
        For patients under-age, signed informed consent from both the patient and the patient's
        parent/legal guardian is required 2. Male or Female, ≥12 years of age 3. Documented
        diagnosis of asthma for at least 6 months prior to Visit 1 4. Patients who are in need of
        Step 2 treatment according to Global Initiative for Asthma guidelines 5. Patients treated
        with 'as needed' inhaled short-acting bronchodilator(s) only should have pre-bronchodilator
        Forced Expiratory Volume in one second (FEV1) ≥ 60 % of Predicted Normal (PN) and
        post-bronchodilator FEV1 ≥ 80 % PN 6. Patients treated with low stable dose of inhaled
        corticosteroid or leukotriene antagonist in addition to 'as needed' use of inhaled
        short-acting bronchodilator(s) should have pre-bronchodilator FEV1 ≥80 % PN 7. Patients
        should have reversible airway obstruction 8. To be randomized patients must have used
        Bricanyl Turbuhaler 'as needed' on at least 3 separate days during the last week of the run
        in period. EXCLUSION CRITERIA 1. Patient has a history of life-threatening asthma including
        intubation and intensive care unit admission 2. Patient has had an asthma worsening
        requiring change in treatment other than inhaled short-acting bronchodilator(s) within 30
        days prior to Visit 1 or between Visits 1 and 2; or a treatment other than Bricanyl
        Turbuhaler from Visit 2 until randomization 3. Patient has required treatment with oral,
        rectal or parenteral glucocorticosteroids (GCS) within 30 days and/or depot parenteral GCS
        within 12 weeks prior to Visit 1 4. Smoker (current or previous) with a smoking history of
        ≥ 10 pack years 5. Pregnancy, breast-feeding or planned pregnancy during the study.
Clinical trial NCT02151981 (phase 3, status: active, not recruiting)
Conditions: anticancer treatment
ICD codes: Z01.12, Z92.89, Z75.2, M27.59, Z53.9, Z91.19, M27.51
Drugs: chemotherapy, cross-over to osimertinib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with histologically or cytologically documented NSCLC.

          -  Locally advanced or metastatic NSCLC

          -  Radiological documentation of disease progression following 1st line EGFR TKI
             Treatment without any further treatment

          -  Eligible to receive treatment with the selected doublet-chemotherapy

          -  Central confirmation of T790M+ mutation status

          -  World Health Organization (WHO) performance status 0-1

          -  At least one lesion, not previously irradiated.

        Exclusion Criteria:

          -  • Prior neo-adjuvant or adjuvant chemotherapy treatment within 6 months prior of
             starting 1st EGFR TKI treatment

          -  Treatment with more than one prior line of treatment for advanced NSCLC

          -  Treatment with an approved EGFR-TKI (e.g.,erlotinib, gefitinib, afatinib) within 8
             days or approximately 5x half-life of the first dose of study treatment

          -  Any investigational agents or other anticancer drugs from a previous treatment regimen
             or clinical study within 14 days of the first dose of study treatment

          -  Previous treatment with Osimertinib, or a 3rd generation EGFR TKI

        For subjects who cross-over to Osimertinib:

          -  Once subjects on the platinum-based doublet chemotherapy arm are determined to have
             objective radiological progression according to RECIST 1.1 by the investigator and
             confirmed by independent central imaging review.

          -  At least 14 days since last dose of platinum-based doublet chemotherapy
Clinical trial NCT02152930 (phase 3, status: terminated)
Conditions: intermittent claudication
ICD codes: I70.211, I70.212, I70.213, I70.218, I70.219, I70.611, I70.612
Drugs: omega-3 fatty acids
SMILES: CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
Reason stopped: 
    low recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18

          -  Newly diagnosed intermittent claudication

          -  Ankle Brachial Index < 0.8 at rest or > 0.15 decrease after exercise

          -  Able to perform standardised treadmill walking test for 2 min

          -  Written informed consent

        Exclusion Criteria:

          -  Unable to fill out a questionnaire (cognitive impairment or insufficient knowledge of
             the Dutch language)

          -  Heart failure or unstable cardiac status (angina pectoris class III or IV or recent
             myocardial infarction < 3 months)

          -  Any illness with rapid evolution or a life expectancy < 3 months

          -  Recent cerebrovascular accident (< 3 months)

          -  Current use of fish oil supplements or > 2 times a week dietary fish

          -  Pregnancy

          -  Fish, soybean or peanut allergy

          -  Contra indications for the use of omega-3 fatty acids

          -  Use of oral anticoagulants (coumarin derivatives)
Clinical trial NCT02158533 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: high dose alks 5461, low dose alks 5461, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a Body Mass Index (BMI) of 18.0 to 40.0 kg/m2, inclusive

          -  Agree to use an acceptable method of contraception for the duration of the study

          -  Have a Major Depressive Disorder (MDD) primary diagnosis

          -  Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the
             current Major Depressive Episode (MDE)

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Have a current primary Axis-I disorder other than MDD

          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid
             antagonists (eg, naloxone, naltrexone) within 14 days

          -  Have received electroconvulsive therapy treatment within the last 2 years or received
             more than one course of electroconvulsive treatment during lifetime

          -  Have attempted suicide within the past 2 years

          -  Have a positive test for drugs of abuse

          -  Are pregnant, planning to become pregnant, or breastfeeding

          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid
             antagonists (eg, naltrexone, naloxone)

          -  Have had a significant blood loss or blood donation within 60 days

          -  Additional criteria may apply
Clinical trial NCT02158546 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: alks 5461, placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a Body Mass Index (BMI) of 18.0 to 40.0 kg/m2, inclusive

          -  Agree to use an acceptable method of contraception for the duration of the study

          -  Have a Major Depressive Disorder (MDD) primary diagnosis

          -  Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the
             current Major Depressive Episode (MDE)

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Have a current primary Axis-I disorder other than MDD

          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid
             antagonists (eg, naloxone, naltrexone) within 14 days

          -  Have received electroconvulsive therapy treatment within the last 2 years or received
             more than one course of electroconvulsive treatment during lifetime

          -  Have attempted suicide within the past 2 years

          -  Have a positive test for drugs of abuse

          -  Are pregnant, planning to become pregnant, or breastfeeding

          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid
             antagonists (eg, naltrexone, naloxone)

          -  Have had a significant blood loss or blood donation within 60 days

          -  Additional criteria may apply
Clinical trial NCT02161185 (phase 3, status: terminated)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: usl261
SMILES: CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Reason stopped: 
    study terminated due to slow enrollment. there were no safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Has a competent, adult caregiver(s) who is able to recognize and observe the subject's
             seizure cluster episodes

          2. Has an established diagnosis of partial or generalized epilepsy that includes all the
             following:

               -  A documented history of seizure clusters lasting a minimum of 10 minutes, seizure
                  cluster pattern is observable, stereotyped, and recognizably different from the
                  subject's other non-cluster seizure activity (if any)

               -  A second seizure in the seizure cluster typically occurs within 6 hours from the
                  time of recognition

               -  A seizure cluster pattern composed of multiple (≥ 2) partial or generalized
                  seizures

               -  A seizure cluster pattern established >3 months before Visit 1

               -  A frequency of ≥ 3 stereotyped seizure clusters during the year before Visit 1

               -  At least 1 stereotyped seizure cluster occuring ≤ 4 months before Visit 1

          3. Currently on a stable regimen of AED(s) that includes a benzodiazepine

          4. Weight is 40 kg to 125 kg, inclusive

        Exclusion Criteria:

          1. Has a neurological disorder that is likely to progress in the next year

          2. Has a severe chronic cardio-respiratory disease

          3. Has a psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1

          4. Has a history of their stereotypical seizure cluster progressing to status epilepticus
             within 2 years before Visit 1

          5. Has a history of acute narrow-angle glaucoma

          6. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before
             Visit 1 or a suicide attempt in the past 5 years
Clinical trial NCT02161705 (phase 3, status: terminated)
Conditions: postoperative pain, postoperative nausea and vomiting, quality of life
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: ropivacaine, saline
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    poor accrual due to change in standard of care procedure.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Be Female aged 18-100 years.

          -  Choose mastectomy followed by bilateral immediate tissue expander breast
             reconstruction.

          -  Have no inflammatory breast cancers.

          -  Be aware of the nature of her malignancy.

          -  Understand the study purpose, requirements, and risks.

          -  Be able and willing to give informed consent.

        Exclusion Criteria:

          -  Any concurrent opioid analgesic use (baseline opioid use must be 0 to be eligible).

          -  Liver dysfunction and/ or cirrhosis.

          -  Renal insufficiency, with creatinine greater than 1.5 mg/mL.

          -  Patients weighing less than 50 Kg.

          -  Concurrent use of the SSRI antidepressant fluvoxamine (Luvox).